A detailed history of Knott David M Jr transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Knott David M Jr holds 39,036 shares of VKTX stock, worth $1.65 Million. This represents 0.87% of its overall portfolio holdings.

Number of Shares
39,036
Previous 76,036 48.66%
Holding current value
$1.65 Million
Previous $4.03 Million 38.7%
% of portfolio
0.87%
Previous 1.61%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$49.84 - $70.47 $1.84 Million - $2.61 Million
-37,000 Reduced 48.66%
39,036 $2.47 Million
Q2 2024

Aug 12, 2024

SELL
$47.39 - $80.2 $1.2 Million - $2.04 Million
-25,400 Reduced 25.04%
76,036 $4.03 Million
Q1 2024

May 14, 2024

SELL
$17.4 - $94.5 $2.95 Million - $16 Million
-169,386 Reduced 62.55%
101,436 $8.32 Million
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $787,867 - $1.67 Million
85,267 Added 45.95%
270,822 $5.04 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $1.2 Million - $1.76 Million
110,006 Added 145.61%
185,555 $2.05 Million
Q2 2023

Aug 11, 2023

SELL
$14.84 - $24.79 $1.85 Million - $3.09 Million
-124,615 Reduced 62.26%
75,549 $1.23 Million
Q1 2023

May 11, 2023

SELL
$8.08 - $17.33 $1.47 Million - $3.14 Million
-181,457 Reduced 47.55%
200,164 $3.33 Million
Q4 2022

Feb 13, 2023

BUY
$2.72 - $9.4 $217,104 - $750,289
79,818 Added 26.45%
381,621 $3.59 Million
Q3 2022

Nov 10, 2022

BUY
$2.55 - $3.89 $89,250 - $136,150
35,000 Added 13.12%
301,803 $821,000
Q2 2022

Aug 11, 2022

BUY
$2.11 - $3.15 $81,659 - $121,908
38,701 Added 16.97%
266,803 $771,000
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $60,000 - $97,600
20,000 Added 9.61%
228,102 $684,000
Q4 2021

Feb 11, 2022

BUY
$4.6 - $6.72 $957,269 - $1.4 Million
208,102 New
208,102 $957,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Knott David M Jr Portfolio

Follow Knott David M Jr and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.